Can I Take Rhodiola with Repatha (Evolocumab)?

What Is Repatha (Evolocumab) and How Does It Work?

Evolocumab is a fully human monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme responsible for degrading LDL receptors on hepatocytes. By blocking PCSK9, evolocumab allows LDL receptors to recycle to the cell surface, dramatically lowering circulating LDL-cholesterol.

The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond diet and maximally tolerated statin therapy. [1]

Dosing and Administration

Standard dosing is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly via a single-use prefilled autoinjector or the Pushtronex on-body infusor. Homozygous familial hypercholesterolemia may require 420 mg monthly from the outset.

Metabolic Pathway: Why CYP450 Does Not Apply

This distinction is the single most important pharmacokinetic fact for any supplement interaction question. Evolocumab is a 144 kDa IgG2 monoclonal antibody. It is not metabolized by hepatic cytochrome P450 enzymes, P-glycoprotein, or renal transporters. Instead, it is broken down through endosomal proteolytic degradation, the same pathway used to clear all endogenous IgG. [2]

That means any supplement that inhibits or induces CYP3A4, CYP2C9, or CYP2D6 has no route through which to alter evolocumab plasma levels. Rhodiola's effects on those enzymes, modest as they are, simply do not reach evolocumab.

What Is Rhodiola Rosea and Why Do Patients Take It?

Rhodiola rosea is a perennial flowering plant used for centuries in Scandinavian and Russian traditional medicine as an adaptogen, a class of botanical agents thought to help the body resist physical and mental stress. Active constituents include rosavin, salidroside, and tyrosol.

Patients prescribed Repatha often take rhodiola hoping to reduce fatigue, support mood during statin-combination therapy, or manage the psychological burden of a cardiovascular diagnosis. A 2012 systematic review in Phytomedicine (N=11 trials) found improvements in physical performance and mild antifatigue effects, though most trials were short and of modest quality. [3]

Pharmacological Activities Relevant to Drug Interactions

Rhodiola is not inert. Three mechanisms deserve attention in any person managing cardiovascular disease:

Monoamine oxidase inhibition. Salidroside and rosavin have demonstrated weak inhibitory activity against monoamine oxidase A (MAO-A) and MAO-B in cell-based assays. [4] MAO-A preferentially degrades serotonin and norepinephrine. Inhibiting it even partially raises the theoretical risk of serotonin accumulation when rhodiola is combined with serotonergic drugs.

Serotonergic activity. Rodent models show rhodiola extract increases hippocampal serotonin and dopamine levels. The clinical magnitude in humans is unknown, but the direction of effect is consistent across multiple preclinical data sets. [5]

CYP enzyme modulation. In vitro, salidroside shows mild inhibitory effects on CYP3A4. The clinical relevance of this finding at typical supplement doses (200 to 600 mg/day) has not been established in human pharmacokinetic studies, and it does not apply to evolocumab for the reasons described above.

Cardiovascular Effects of Rhodiola

A small 2013 double-blind RCT published in Phytotherapy Research (N=80) found rhodiola rosea extract (576 mg/day for 42 days) produced modest reductions in exercise-related heart rate and blood pressure without serious adverse events. [6] No trial has specifically studied rhodiola in patients on PCSK9 inhibitors.

Is There a Direct Interaction Between Rhodiola and Evolocumab?

No direct interaction, pharmacokinetic or pharmacodynamic, has been documented in any peer-reviewed clinical study or case report as of this writing. That is not the same as saying the combination is proven safe. Absence of published interaction data is common with supplements, partly because large post-marketing surveillance systems are not designed to capture them.

Pharmacokinetic Verdict: No Meaningful Risk

Because evolocumab does not travel through CYP450 pathways, rhodiola cannot accelerate or inhibit its clearance. Evolocumab's median time to maximum serum concentration after a 140 mg subcutaneous dose is 3 to 4 days, and its elimination half-life is approximately 11 to 17 days. None of these parameters is enzymatically regulated in a way that rhodiola's constituents could modify. [2]

Pharmacodynamic Verdict: Low Risk, One Caveat

Evolocumab has no central nervous system activity. It does not affect serotonin, dopamine, or norepinephrine signaling. Rhodiola's serotonergic and MAOI-like properties therefore do not intersect with evolocumab's mechanism of action.

The caveat is the broader medication list. Cardiovascular patients are often prescribed antidepressants concurrently. The American Heart Association's 2008 science advisory noted that depression is present in roughly 20% of post-myocardial infarction patients and may affect up to 33% of those with heart failure. [7] If a patient takes an SSRI, SNRI, or tricyclic antidepressant alongside evolocumab, adding rhodiola introduces a third serotonergic element. That combination warrants prescriber review, not because of evolocumab, but because of the antidepressant.

Evaluating the Evidence: What the Clinical Trials Tell Us

FOURIER: The Core Evolocumab Safety Data

The most rigorous long-term safety evidence for evolocumab comes from FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized, double-blind, placebo-controlled trial in 27,564 patients with established ASCVD on statin therapy. Over a median 2.2 years of follow-up, evolocumab reduced LDL-C by 59% vs. Placebo (from a median 92 mg/dL to 30 mg/dL) and cut the composite of major cardiovascular events by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). [8]

Adverse event rates for injection-site reactions (2.1% vs. 1.6% placebo), myalgia, neurocognitive events, and new-onset diabetes were similar between groups. FOURIER did not assess any supplement co-administration, so it cannot rule in or rule out rhodiola interactions, but it confirms that evolocumab's safety profile at the pharmacodynamic level is well-characterized.

ODYSSEY OUTCOMES: Alirocumab Data With Relevance to Class Safety

ODYSSEY OUTCOMES (N=18,924), which evaluated alirocumab (a different PCSK9 inhibitor) after acute coronary syndrome, provides supporting class-level evidence that PCSK9 inhibitors carry a favorable safety profile over multi-year follow-up. [9] Because alirocumab shares the same large-molecule, CYP450-independent metabolic route as evolocumab, its interaction-free record with common medications is relevant context.

Rhodiola RCT Evidence: Where the Gaps Are

No published RCT has enrolled patients on PCSK9 inhibitors and tested rhodiola supplementation. The existing rhodiola trial base, summarized in a 2011 Cochrane-adjacent review by Hung and colleagues, found 11 eligible trials totaling fewer than 600 participants, with follow-up ranging from 5 days to 6 weeks. [3] No trial tracked lipid panels or cardiovascular endpoints. That gap in the literature is real and should make clinicians appropriately cautious rather than dismissive.

Who Is Most at Risk When Combining Rhodiola with Their Medication Regimen?

The following clinical decision framework helps prescribers stratify patients:

Tier 1: No added risk. Patient takes evolocumab only, with a statin, with ezetimibe, or with bempedoic acid, and no serotonergic or MAO-sensitive drugs. Rhodiola at standard doses (200 to 400 mg/day standardized to 3% rosavins) is unlikely to cause a clinically meaningful interaction. Disclosure to the prescriber is still appropriate.

Tier 2: Moderate caution needed. Patient takes evolocumab plus one serotonergic agent such as an SSRI (sertraline, escitalopram), SNRI (venlafaxine, duloxetine), or low-dose tricyclic (amitriptyline for sleep). Adding rhodiola raises the theoretical serotonergic burden. The prescriber should review whether the indication for rhodiola is evidence-supported and whether a non-serotonergic alternative (such as ashwagandha, which lacks significant MAO activity) might serve the same purpose.

Tier 3: Avoid or seek specialist input. Patient takes evolocumab plus a formal MAOI antidepressant (phenelzine, tranylcypromine, selegiline) or linezolid (used for gram-positive infections and carrying significant MAOI activity). Rhodiola is contraindicated in combination with MAOIs per the Natural Medicines Database. The addition of even mild exogenous MAO inhibition carries risk of serotonin syndrome.

Tier 4: Insufficient data. Patient takes evolocumab plus medications metabolized by CYP3A4 with narrow therapeutic windows (cyclosporine, certain HIV antiretrovirals). Rhodiola's in vitro CYP3A4 effects are uncharacterized at clinical doses in this population. Specialist pharmacist review is appropriate before adding the supplement.

What Monitoring Looks Like If You Are Already Taking Both

If a patient is already taking rhodiola alongside evolocumab without prior prescriber input, the following monitoring approach is reasonable:

Lipid Panel Timing

Evolocumab's full LDL-C lowering effect is typically evident within 4 weeks of initiating therapy. Patients should continue their scheduled lipid monitoring (every 6 to 12 months once stable, per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol) to confirm target LDL-C is being maintained. [10] Rhodiola does not affect LDL-C, so a panel outside target should prompt a review of statin adherence and dietary factors before suspecting the supplement.

Symptom Monitoring for Serotonergic Effects

Patients co-administering any serotonergic drug should know the warning signs of serotonin syndrome: agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, or diarrhea. These symptoms typically develop within hours of a new drug or dose change. If any appear, stop the supplement and seek same-day medical evaluation.

Injection Site and Immune Monitoring

Evolocumab's most common adverse effects are injection-site reactions and nasopharyngitis. These are immune-mediated, not pharmacologically related to rhodiola. A new rash or injection-site swelling should be reported to the prescriber as a potential evolocumab adverse effect, not attributed to the supplement.

Guidance from Named Clinical Sources

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD at very high risk, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add a PCSK9 inhibitor." [10] That guideline does not address supplement co-administration, reflecting the broader gap in formal guidance on this topic.

Dr. Nissen and colleagues, writing in JAMA in 2016 on the GLAGOV trial (N=968), observed that evolocumab produced "significant regression of coronary atherosclerosis" at 78 weeks compared with placebo (mean percent atheroma volume reduced by 0.95% vs. Increased by 0.05%; P<0.001). [11] That degree of benefit makes uninterrupted, full-dose evolocumab therapy a high clinical priority, and any supplement that might inadvertently lead a patient to skip doses or distrust the drug is worth discussing openly.

Practical Steps Before Adding Rhodiola to Your Regimen

Taking a few concrete steps protects both safety and the therapeutic value of evolocumab:

1. List every medication and supplement for your prescriber at each visit. Include rhodiola's dose, brand, and standardization percentage if available.
2. Confirm your antidepressant status. If you take any drug in the SSRI, SNRI, TCA, or MAOI class, your prescriber needs to know before you start rhodiola.
3. Choose a standardized product. The supplement industry is not regulated for potency the same way pharmaceuticals are. Choose a product standardized to at least 3% rosavins and 1% salidroside, and prefer brands with third-party testing (USP, NSF, or ConsumerLab verification).
4. Start at the lowest effective dose. Most adaptogen trials use 200 to 400 mg/day. Starting at 200 mg/day for two weeks before increasing gives time to notice any unexpected symptoms.
5. Do not stop Repatha without prescriber guidance. No evidence suggests rhodiola interferes with evolocumab's mechanism. Stopping a PCSK9 inhibitor to "play it safe" with a supplement removes proven cardiovascular protection without clinical justification.